Research progress in immune checkpoint inhibitors for the treatment of cervical cancer
10.3760/cma.j.cn121382-20230329-00309
- VernacularTitle:免疫检查点抑制剂治疗宫颈癌的研究进展
- Author:
Xue MENG
1
;
Rong YU
Author Information
1. 内蒙古医科大学，呼和浩特 010000
- Keywords:
Cervical cancer;
Immunocheckpoint inhibitors;
Adverse drug events;
Drug resistance
- From:
International Journal of Biomedical Engineering
2023;46(3):240-244
- CountryChina
- Language:Chinese
-
Abstract:
Cervical cancer is a common gynecological malignancy. Currently, synchronous radiotherapy and chemotherapy based on the single drug cisplatin are the standard treatment regimen for locally advanced cervical cancer. Compared with simple radiotherapy and chemotherapy, the use of immunosuppressive combination regimens in concurrent radiotherapy and chemotherapy is more likely to improve local control and reduce distant metastasis. In recent years, immune checkpoint inhibitors (ICIs) have been widely studied as potential therapeutic targets for cervical cancer. Immunocheckpoint inhibitors can improve the activation of immune cells and enhance the body’s anti-tumor immunity. In this paper, the mechanism of immune checkpoint inhibitors was summarized, and the therapeutic effects of various monoclonal antibodies were reviewed to provide a new perspective for immunotherapy in patients with cervical cancer.
